SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development
The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.
SGS has entered into a collaboration with DiscoverX, an innovative life science company that supplies cell-based assays and services for drug discovery and development. Under the terms of the agreement, SGS and DiscoverX will work together to provide simple and qualified assays for functional comparability, for use in quality control (QC), lot release, and stability testing of biosimilars and biobetters, offering products as well as services.
DiscoverX has developed ready-to-use bioassays for a number of biologic drugs that are set to lose patent protection over the next 10 years. SGS has initiated the evaluation and qualification of these assays and plans to offer these as a service within a Good Manufacturing Practice (GMP) or Good Clinical Practice (GCP) environment for clients. The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures, and enable them to rapidly advance to qualification and assay validation for potency and neutralizing-antibody assays.
“These assays are simple to use and generate accurate, robust and reproducible results, which can accelerate the process of demonstrating biosimilarity, and the development of lot release assays for drug candidates,” commented Fiona Greer, Global Director, Biopharma Services Development at SGS. “By combining SGS’s vast knowledge in bioanalysis, with the experience DiscoverX has in developing innovative cell-based assays, this collaboration will bring value to clients of both companies.”
“DiscoverX has developed industry-leading cell-based assays for bio-comparability and lot release testing of biosimilar drugs. These assays are available to our clients to use as a product and now, partnering with SGS allows us to offer these assays as GMP and GCP services as well,” said Dr. Todd Nelson, CEO of DiscoverX. Dr Nelson continued: “This partnership will provide simple, qualified, fit-for-purpose bioassays for QC lot release and stability testing of biosimilars and biobetters to clients globally.”
Data on the first assay qualification studies will be presented at the CASSS Bioassays 2016 Conference in Silver Spring, MD. SGS will offer the functional comparability assay services to clients under GMP/GCP from its Poitiers, France laboratory. This new service will be supported by SGS’s existing characterization and analytical capabilities across its global network.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.